Childhood cancers, though less common than adult cancers, remain a leading cause of cancer-related deaths in children, with survival rates for some types still suboptimal. Despite advancements in treatment, current therapies often result in significant acute and long-term side effects, highlighting the need for more targeted, less toxic treatments. This chapter explores the role of basic science in advancing childhood cancer research, focusing on the molecular mechanisms driving tumor initiation, progression, and therapy resistance. Key areas of investigation include cancer genetics, epigenetics, and cancer stem cells, with emerging research identifying new therapeutic targets for precision medicine. Recent breakthroughs in molecular profiling, immunotherapy, and gene-editing technologies offer promising avenues for developing targeted treatments, such as CAR-T cell therapy and immune checkpoint inhibitors. Additionally, research models, including patient-derived xenografts and organoids, are enhancing drug testing and facilitating personalized treatment strategies. Despite these advancements, challenges remain, including the molecular diversity of childhood cancers and the underfunding of pediatric cancer research. Future directions in childhood cancer research will likely focus on improving earlier detection, refining personalized treatment approaches, developing multimodal therapies that combine immunotherapy, targeted therapies, and conventional treatments, and refinements in diagnostic technologies. With continued investment and innovative research, there is hope for improved outcomes and reduced side effects for pediatric and adolescent cancer patients.